摘要
目的:探讨CALR、JAK2、MPL不同基因突变原发性血小板增多症(ET)患者的临床特征、实验室及骨髓病理学特点。方法:2015年1月-2017年12月于我院确诊的ET患者120例,其中JAK2基因突变76例,CALR基因突变40例,MPL基因突变2例,3基因突变阴性患者2例.比较JAK2基因突变ET与CALR基因突变ET临床及实验室特点,采用Nikon cclipsc显微镜进行病理切片观察,每个病理切片取10个不同高倍视野进行巨核计数,巨核细胞集簇数并测量每个高倍视野最大巨核细胞直径。结果:ET患者中,CALR突变组与JAK2突变组相比较,白细胞数、血红蛋白水平均明显降低(P=0.001,P=0.001),男性血小板数明显升高(P=0.04);每高倍镜视野中巨核细胞平均值明显降低(P=0.001),平均巨核细胞集簇数明显减少(P=0.001)。CALR突变组血栓事件显著低于JAK2突变组(7.5%vs 18.4%)(P=0.03)。结论:中国ET患者中,CALR基因突变者较JAK2基因突变者临床特征和血液病理改变存在差异,临床意义值得探索。
Objective:To investigate the clinical characteristics,laboratorial and bone marrow pathological features of primary thrombocytopenia(ET)patients with different mutations of CALR,JAK2 and MPL genes.Methods:The chinical data of 120 cases of ET in Jiangsu provincial people’s hospital/The First Affiliated Hospital of Nanjing Medical University from January 2015 to December 2017 were collected and analyzed,including 76 cases with JAK2 gene mutation,40 cases with CALR gene mutation,2 cases with MPL gene mutations,2 cases without gene mutation.Results:Among the ET patients,compared with the JAK2 gene mutation,CALR gene mutation showed statistically significant deareament of white blood cells and hemoglobin(P=0.001,P=0.01)and the male platelets in CALR group showed significant increament(P=0.04).Fourthermore,the average number of megakaryocytes and its cluster numbers in each hight power field of vision showed statistically significant decreament in CALR group as compared with JAK2 group(P=0.001,P=0.001),and thrombotic events in CALR group were signicantly lower than those in JAK2 group(7.5%vs 18.4%)(P=0.03).Conclusion:Mutations of CALR,JAK2 have different clinical characteristics and blood pathological changes of Chinese ET patients,and their clinical significance is worth to explore.
作者
冶秀鹏
王蓉
王全贵
王琰
张建富
乔纯
刘红娟
艾克丹木·艾尔肯
柴星星
陆星雨
刘晓庆
程朗
刘正媛
李叶琼
张春瑜
李芳
何广胜
包慎
YE Xiu-Peng;WANG Rong;WANG Quan-Gui;WANG Yan;ZHANG Jian-Fu;QIAO Chun;LIU Hong-Juan;AI Ke-Danmu·Aierken;CHAI Xing-Xing;LU Xing-Yu;LIU Xiao-Qing;CHEN Lang;LIU Zheng-Yuan;LI Ye-Qiong;ZHANG Chun-Yu;LI Fang;HE Guang-Sheng;BAO Shen(Department of Hematology-Oncology,The First Affiliated Hospital of Northwest University for Nationalities,Ningxia People's Hospital,Yinchuan 750002,Ningxia Hui Autonomous Region,China;Department of Hematology,The First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing 210029,Jiangsu Province,China;Guyuan people's Hospital,Guyuan 756000,Ningxia Hui Autonomous Region,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2020年第4期1326-1331,共6页
Journal of Experimental Hematology
基金
宁夏自然科学基金项目资助(2018AAC03174)
中央高校技术开发与应用项目资助(31920190178)。